Although obesity is an established risk factor for postmenopausal breast cancer, the results of weight loss and breast cancer studies are inconsistent. Therefore, we evaluated associations between weight change and breast cancer risk in postmenopausal women in the Women's Health Initiative Observational Study. METHODS: Postmenopausal women (n = 61,335) who had no prior breast cancer and a normal mammogram had body weight and height measured and body mass index (BMI) calculated at baseline and year 3. Weight change at year 3 was categorized as stable (<5%), loss (≥5%), or gain (≥5%) with further assessment of weight loss intentionality by self-report. Multivariable Cox proportional hazard regression models were used to evaluate relationships between weight change and subsequent breast cancer incidence. RESULTS: During a mean follow-up of 11.4 years with 3061 incident breast cancers, women with weight loss (n = 8175) had a significantly lower risk of breast cancer compared with women whose weight remained stable (n = 41,139) (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.78-0.98; P = .02) with no interaction by BMI. Adjustment for mammography did not alter findings (HR, 0.88; 95% CI, 0.78-0.99) with no significant difference by weight loss intentionality. Weight gain (≥5%) (n = 12,021) was not associated with breast cancer risk (HR, 1.02; 95% CI, 0.93-1.11) but was associated with higher triple-negative breast cancer incidence (HR, 1.54; 95% CI, 1.16-2.05). CONCLUSIONS: Postmenopausal women who lose weight have lower breast cancer risk than those with stable weight. These findings suggest that postmenopausal women who lose weight may reduce their breast cancer risk. Cancer 2019;125:205-212.
INTRODUCTION
Obesity is associated with increased risk of incident postmenopausal breast cancer. 1, 2 Because approximately one third of postmenopausal women in the United States are obese, 3 obesity represents a common and potentially modifiable factor related to breast cancer outcome. However, it has not been established that weight loss in postmenopausal women decreases breast cancer incidence or breast cancer mortality. 4 Findings from observational studies in postmenopausal women examining weight loss and breast cancer incidence are inconsistent. Most recently, an analysis of 67,142 postmenopausal women in the Women's Health Initiative (WHI) clinical trials found no association with subsequent breast cancer incidence in women with weight loss compared with women without weight loss. 5 These mixed findings preclude a strong public health message that postmenopausal women who are overweight or obese could reduce their breast cancer risk by losing weight.
Take Off Pounds Sensibly (TOPS), a nationally available nonprofit weight loss program, has demonstrated that weight loss above 5% of initial weight can be achieved and maintained for several years. 6 This modest amount of weight loss has been associated with health benefits including reduction in cardiovascular disease risk factors, 7 decreased progression of glucose intolerance to type 2 diabetes, 8 and decreased severity of obstructive sleep apnea. 9 Based on
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PARTICIPANTS AND METHODS
Details of the design and conduct of the WHI Observational Study have been described previously. 10 Briefly, 93,676 women ages 50-79 years with anticipated 3-year survival who were not eligible or interested in participating in the WHI clinical trials were recruited from 40 clinical centers in the United States between 1993 and 1998. The study was approved by institutional review boards at the clinical centers, and all participants provided written consent.
MEASURES
Information on demographics and breast cancer risk were self-reported using questionnaires at baseline. Information on medication use was collected during interviews. Mammograms were not protocol mandated, but information on mammography frequency was collected annually. Measured height and weight were recorded at baseline and year 3 and were used to calculate body mass index (BMI, kg/m 2 ). Percent weight change was calculated as measured weight at year 3 subtracted from measured weight at baseline divided by measured weight at baseline. The determined percent weight change variable categories were: weight gain (≥5%); weight loss (≥5%); and stable weight (<5% loss or gain). In addition, at the 3-year follow-up, participants were asked in a questionnaire, "In the past 2 years, did you gain or lose 5 or more pounds?" and "Was the change intentional or unintentional?" This information was used to categorize weight loss as intentional or unintentional, Clinical outcomes were ascertained annually, and reported breast cancers were confirmed after medical record review by trained physician adjudicators at the clinical centers. Final adjudication and coding was performed at the WHI Clinical Coordinating Center.
11 Estrogen receptor (ER), progesterone receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) status was based on review of local laboratory reports.
Exclusion criteria for the WHI Observational Study included prior cancer (except nonmelanoma skin cancer; n = 10,197); no follow-up information (n = 422); missing values for exposures of interest (baseline weight, n = 413; year 3 weight, n = 13,629; intentional weight loss, Cancer January 15, 2019 n = 4288); BMI <18.5 kg/m 2 (n = 2416); and breast cancer diagnosis, death, or loss to follow-up between baseline and year 3 (n = 976). After exclusions, 61,335 women remained for the analysis (Fig. 1) .
Incident invasive breast cancer diagnosed after the year 3 visit was the primary study outcome. Participants were observed from the year 3 visit until breast cancer diagnosis, date of death, loss to follow-up, or end of follow-up (September 30, 2015). Follow-up continued per the original protocol through the original trial completion date of March 31, 2005. Ongoing follow-up required 2 additional written consents at 2005 and 2010, which were obtained from 73% and 88% of surviving participants, respectively.
Statistical Analyses
Baseline characteristics are described by postbaseline 3-year weight change category (weight loss, weight gain, stable weight). To estimate associations between weight change category and breast cancer incidence, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were generated using Cox proportional hazards models adjusted for relevant covariates. Additional analyses evaluated weight loss intentionality and breast cancer incidence similarly. All statistical tests were 2-sided.
In multivariable models, we adjusted for results from the Breast Cancer Risk Assessment Tool (which included age at enrollment, race/ethnicity, age of menarche, age at birth of first live child, number of first-degree relatives with breast cancer, and number of previous breast biopsies), level of education, smoking pack-years, recreational physical activity, alcohol consumption, history of hormone therapy use, parity, and baseline BMI. Weight change associations with breast cancer incidence were also examined by subtypes defined by baseline BMI cate- ), race/ethnicity, age group (50-69 years, ≥70 years) and menopausal hormone therapy use. Because weight change associations were examined in 4 subgroups, fewer than 1 would be accepted to be positive by chance. Sensitivity analyses were adjusted for frequency of mammography and excluded breast cancers diagnosed within the first year of follow-up (after the year 3 visit).
RESULTS
Baseline characteristics by weight change categories from baseline to year 3 are listed in Table 1 . Compared with women who had stable weight, women who had 5% weight gain were more likely to be younger, black, heavier smokers, and younger at their first child's birth. Compared with women who had stable weight, women who had intentional weight loss were more likely to have a higher BMI but less likely to be physically active or have used any menopausal hormone therapy (P < .01).
The mean weight loss from baseline to year 3 for the 4829 women reporting intentional weight loss was 19.56 pounds (standard deviation [SD], 27.12), whereas the mean weight loss for the 3346 women reporting unintentional weight loss was 16.90 pounds (SD, 18.69).
Compared with weight at year 3, self-reported weight at year 6 for the intentional weight loss group was +2.55 pounds (SD, 13.68) and for the unintentional weight loss group was +1.82 pounds (SD, 12.03). Thus, most early weight loss was maintained through year 6 (Supporting Table 1 ).
During a mean follow-up of 11.4 years from the year 3 visit, 3061 women developed invasive breast cancer. The mean time from year 3 weight determination to breast cancer diagnosis was 6.47 years (range, 0.005-17.0 years). In multivariable analyses, compared with women with stable weight (n = 41,139), women with weight loss (n = 8175) had a significantly lower breast cancer risk (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.78-0.98; P = .02) ( Table 2) . Adjustment for mammography did not alter findings (HR, 0.88; 95% CI, 0.78-0.99). Statistical tests between intentional and unintentional weight loss and breast cancer incidence yielded no significant difference (P = .2) with HRs < 1 for both intentional and unintentional weight loss and breast cancer risk. Results were also similar after excluding breast cancers diagnosed within the first year of follow-up (after the year 3 visit) and in analyses adjusting for mammogram frequency. Weight gain (n = 12,021) was not associated with higher overall breast cancer risk but was associated with a higher risk of triple-negative breast cancer (HR, 1.54; 95% CI, 1.16-2.05).
Breast cancer characteristics are shown in Supporting Table 2 with associations (HR 95% CI) shown in Table 3 . The risk of triple negative breast cancers was highest in the weight gain group (HR 1.54 95% CI 1.16-2.05). Weight change association with breast cancer incidence was examined in 4 subgroups: baseline BMI (normal, overweight, obese), race/ethnicity, age group (50 to ≤70 years, 70 years) and hormone therapy use and findings are shown in Table 4 . No interaction term test was statistically significant. Abbreviations: BMI, body mass index; MET, metabolic equivalent of task. Data are presented as n (%) unless noted otherwise. Some categories do not add up to the total number of cases due to missing data. P values for all difference tests were <.01 except for "Female relative with breast cancer" (P = .4).
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DISCUSSION
In this large prospective study of postmenopausal women, compared with women with stable weight, women with weight loss of ≥ 5% were at a lower risk for invasive breast cancer. There was no significant interaction between weight loss and intentionality of weight loss with respect to breast cancer risk. The current findings are consistent with those from bariatric surgery where the substantial weight loss associated with the procedure in severely obese women has been associated with lower breast cancer risk, supporting the benefits of substantial weight loss (usually >20 kg). 12 Our current findings suggest benefit for smaller degrees of weight loss achievable without surgery.
The association of weight loss with reduction in breast cancer risk in postmenopausal women is supported by findings from the WHI Dietary Modification Trial, 13 where 48,835 women were randomized to a dietary intervention based on a low-fat eating plan or to a usual diet control in a breast cancer primary prevention trial which were recently updated. 14, 15 During the mean 8.5-year Cancer January 15, 2019 dietary intervention period, women in the dietary intervention group significantly reduced their fat intake compared with women in the usual diet control group, which was associated with a statistically significant (3%) weight loss. After a mean 16.1-year cumulative follow-up with 3030 incident breast cancers, deaths after breast cancer were significantly reduced in the dietary intervention group, as measured from randomization 14 or from breast cancer diagnosis. 15 The current finding that weight loss determined over a relatively short 3 year period was associated with a significantly lower breast cancer incidence differs somewhat from findings previously reported from analyses in the separate WHI Clinical Trials population where weight loss was not associated with lower breast cancer incidence. 5 The demographic characteristics of the WHI Clinical Trial and Observational Study participants are comparable. However, findings in the WHI Clinical Trial report are based on serial body weight measures obtained annually for about 12 years from clinical trial initiation in 1993 through 2005. As a group, women in the United States lose weight beginning in the seventh decade of life. 16 Because 23% of women in the WHI Clinical Trials were between 70 and 79 years of age at entry between 1993 and 1998, the report by Neuhouser and colleagues 5 included a much larger contribution of body weight determinations in older women who more commonly experience involuntary weight loss, for both medical and social reasons (such as death of spouse, change in economic status, poor oral health, and activities of daily living disability 17 ). Thus, the findings from the WHI Clinical Trial, which incorporated cumulative weight change over 2 decades, are not directly comparable to the current report on relatively short-term weight change in a younger population.
The current analyses examined weight loss by intentionality because unintentional weight loss, especially in older individuals, is correlated with increased morbidity and mortality and may contribute to reverse causality. 17 In previous analyses in the same WHI Observational Study cohort, 18 overall weight loss 5% was associated with significantly lower endometrial cancer risk (HR, 0.71; 95% CI, 0.54-0.95); however, for endometrial cancer, the association was stronger in women reporting intentional (HR, 0.60; 95% CI, 0.42-0.86) compared with unintentional weight loss (HR, 0.94; 95% CI, 0.62-1.41). The findings regarding weight loss intentionality appear different from those observed for breast cancer in the current report. However, in the prior endometrial cancer report and the current breast cancer report, the HRs for both cancers were <1 for intentional as well as unintentional weight loss, and no significant interaction was seen. Taken together, these findings suggest additional larger studies are needed to provide a more definitive answer regarding the role of intentional versus unintentional weight loss in cancer risk. Cancer January 15, 2019
Based on our review, weight loss intentionality and breast cancer risk have been addressed in only 1 previous prospective study, the Iowa Women's Health Study. 19 That study used recalled weight change for both prior and current weight over a 35-year period and observed that women with an intentional weight loss of ≥20 lbs had a 19% lower risk of breast cancer (RR, 0.81; 95% CI, 0.66-1.00), whereas unintentional weight loss was not associated with lower breast cancer risk. 19 In contrast to recalled weight change in that report, in the current study, we evaluated serial measured weights with intentionality over a relatively short, defined 3-year period.
Study strengths include the large population of postmenopausal women, adjustment for breast cancer risk factors, serial measured body weights, adjudicated breast cancers, weight loss intentionality linked to body weight change, long follow-up, and large number of breast cancer cases.
Our study has some limitations. First, weight was measured at baseline and year 3 only, though most of the weight loss had been sustained by year 6 according to self-reporting. Also, the observational study design precludes causal inference. Because we have no strong biological rationale for the association between weight gain and increasing only triple-negative breast cancer, we now suggest this finding should be interpreted with caution. Although measured weight loss was available for a relatively short period before breast cancer diagnosis, there is evidence that short-term interventions may affect undiagnosed cancer, which influences subsequent health outcomes 5 to 10 years later. Results from a WHI randomized trial evaluating menopausal hormone therapy found that 5.6 years (mean) use of combined estrogen plus progestin significantly increased breast cancer risk, which persisted through 13 years of follow-up (HR, 1.37; 95% CI, 1.06-1.77). 20 Also, in a randomized, placebo-controlled breast cancer primary prevention trial (MAP.3), after median follow-up of only 36 months, compared with placebo, the aromatase inhibitor exemestane reduced breast cancer incidence by 65% (P = .002). 20 Regarding randomized weight reduction trials in populations without cancer, a recent meta-analysis of 45 trials found that behavioral interventions that incorporate both diet and physical activity can achieve significant, maintained weight loss up to 24 months. 21 Taken together with current study findings, these results suggest that a short-term lifestyle intervention may similarly reduce the progression of undiagnosed breast cancers. The similar findings of lower endometrial cancer risk with weight loss determined in the same 3-year period 18 also supports the current results associating weight loss in postmenopausal women with lower breast cancer risk.
In conclusion, weight loss in postmenopausal women is associated with lower breast cancer risk. These findings suggest that interventions in postmenopausal women designed to generate weight loss may result in a reduction in breast cancer risk.
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